APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroendocrine Tumor Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neuroendocrine Tumor Drug Market Outlook and Growth Opportunities 2026

19 December 2025200 pages

Choose your research edition.

Industry ResearchNeuroendocrine Tumor Drug Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroendocrine Tumor Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Neuroendocrine Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroendocrine Tumor Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroendocrine Tumor Drug Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Neuroendocrine Tumor Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neuroendocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuroendocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroendocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neuroendocrine Tumor Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neuroendocrine Tumor Drug market include Exelixis, Inc., Foresee Pharmaceuticals, LLC, Hutchison MediPharma Limited, Intezyne, Inc, INVENT Pharmaceuticals, Inc., Ipsen S.A., Karyopharm Therapeutics, Inc., Lexicon Pharmaceuticals, Inc. and Midatech Pharma Plc ., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neuroendocrine Tumor Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuroendocrine Tumor Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuroendocrine Tumor Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuroendocrine Tumor Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuroendocrine Tumor Drug Segment by Company

Exelixis, Inc.

Foresee Pharmaceuticals, LLC

Hutchison MediPharma Limited

Intezyne, Inc

INVENT Pharmaceuticals, Inc.

Ipsen S.A.

Karyopharm Therapeutics, Inc.

Lexicon Pharmaceuticals, Inc.

Midatech Pharma Plc .

Millennium Pharmaceuticals, Inc.

MolMed S.p.A.

Northwest Biotherapeutics, Inc.

OctreoPharm Sciences GmbH

OXiGENE, Inc.

Jiangsu Hengrui Medicine Co., Ltd.

Novartis AG

Eisai

Neuroendocrine Tumor Drug Segment by Type

mTOR Protein Inhibitors

Tyrosine Kinase 3 Inhibitors

Growth Hormone Releasing Factor Antagonists

Somatostatin Receptor Agonists

Somatostatin Receptor Antagonists

Others

Neuroendocrine Tumor Drug Segment by Application

Hospital

Clinic

Others

Neuroendocrine Tumor Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Neuroendocrine Tumor Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neuroendocrine Tumor Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neuroendocrine Tumor Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Neuroendocrine Tumor Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Tumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neuroendocrine Tumor Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuroendocrine Tumor Drug industry.

Chapter 3: Detailed analysis of Neuroendocrine Tumor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neuroendocrine Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neuroendocrine Tumor Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neuroendocrine Tumor Drug Industry Trends Table 2. Neuroendocrine Tumor Drug Industry Drivers Table 3. Neuroendocrine Tumor Drug Industry Opportunities and Challenges Table 4. Neuroendocrine Tumor Drug Industry Restraints Table 5. Global Neuroendocrine Tumor Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neuroendocrine Tumor Drug Revenue Share by Company (2021-2026) Table 7. Global Neuroendocrine Tumor Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Neuroendocrine Tumor Drug Sales Volume Share by Company (2021-2026) Table 9. Global Neuroendocrine Tumor Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Neuroendocrine Tumor Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neuroendocrine Tumor Drug Key Company Manufacturing Base & Headquarters Table 12. Global Neuroendocrine Tumor Drug Company, Product Type & Application Table 13. Global Neuroendocrine Tumor Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neuroendocrine Tumor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of mTOR Protein Inhibitors Table 18. Significant Companies of Tyrosine Kinase 3 Inhibitors Table 19. Significant Companies of Growth Hormone Releasing Factor Antagonists Table 20. Significant Companies of Somatostatin Receptor Agonists Table 21. Significant Companies of Somatostatin Receptor Antagonists Table 22. Significant Companies of Others Table 23. Global Neuroendocrine Tumor Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 24. Global Neuroendocrine Tumor Drug Sales Volume by Type (2021-2026) & (W Units) Table 25. Global Neuroendocrine Tumor Drug Sales Volume by Type (2027-2032) & (W Units) Table 26. Global Neuroendocrine Tumor Drug Sales Volume Share by Type (2021-2026) Table 27. Global Neuroendocrine Tumor Drug Sales Volume Share by Type (2027-2032) Table 28. Global Neuroendocrine Tumor Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Neuroendocrine Tumor Drug Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Neuroendocrine Tumor Drug Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Neuroendocrine Tumor Drug Sales Value Share by Type (2021-2026) Table 32. Global Neuroendocrine Tumor Drug Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Hospital Table 34. Significant Companies of Clinic Table 35. Significant Companies of Others Table 36. Global Neuroendocrine Tumor Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 37. Global Neuroendocrine Tumor Drug Sales Volume by Application (2021-2026) & (W Units) Table 38. Global Neuroendocrine Tumor Drug Sales Volume by Application (2027-2032) & (W Units) Table 39. Global Neuroendocrine Tumor Drug Sales Volume Share by Application (2021-2026) Table 40. Global Neuroendocrine Tumor Drug Sales Volume Share by Application (2027-2032) Table 41. Global Neuroendocrine Tumor Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Neuroendocrine Tumor Drug Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Neuroendocrine Tumor Drug Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Neuroendocrine Tumor Drug Sales Value Share by Application (2021-2026) Table 45. Global Neuroendocrine Tumor Drug Sales Value Share by Application (2027-2032) Table 46. Global Neuroendocrine Tumor Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 47. Global Neuroendocrine Tumor Drug Sales by Region (2021-2026) & (W Units) Table 48. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2021-2026) Table 49. Global Neuroendocrine Tumor Drug Sales by Region (2027-2032) & (W Units) Table 50. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2027-2032) Table 51. Global Neuroendocrine Tumor Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Neuroendocrine Tumor Drug Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Neuroendocrine Tumor Drug Sales Value Share by Region (2021-2026) Table 54. Global Neuroendocrine Tumor Drug Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Neuroendocrine Tumor Drug Sales Value Share by Region (2027-2032) Table 56. Global Neuroendocrine Tumor Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Neuroendocrine Tumor Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Neuroendocrine Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 59. Global Neuroendocrine Tumor Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Neuroendocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 61. Global Neuroendocrine Tumor Drug Sales Market Share by Country (2021-2026) Table 62. Global Neuroendocrine Tumor Drug Sales by Country (2027-2032) & (W Units) Table 63. Global Neuroendocrine Tumor Drug Sales Market Share by Country (2027-2032) Table 64. Global Neuroendocrine Tumor Drug Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Neuroendocrine Tumor Drug Sales Value Market Share by Country (2021-2026) Table 66. Global Neuroendocrine Tumor Drug Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Neuroendocrine Tumor Drug Sales Value Market Share by Country (2027-2032) Table 68. Exelixis, Inc. Company Information Table 69. Exelixis, Inc. Business Overview Table 70. Exelixis, Inc. Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Exelixis, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 72. Exelixis, Inc. Recent Development Table 73. Foresee Pharmaceuticals, LLC Company Information Table 74. Foresee Pharmaceuticals, LLC Business Overview Table 75. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Portfolio Table 77. Foresee Pharmaceuticals, LLC Recent Development Table 78. Hutchison MediPharma Limited Company Information Table 79. Hutchison MediPharma Limited Business Overview Table 80. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Portfolio Table 82. Hutchison MediPharma Limited Recent Development Table 83. Intezyne, Inc Company Information Table 84. Intezyne, Inc Business Overview Table 85. Intezyne, Inc Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Intezyne, Inc Neuroendocrine Tumor Drug Product Portfolio Table 87. Intezyne, Inc Recent Development Table 88. INVENT Pharmaceuticals, Inc. Company Information Table 89. INVENT Pharmaceuticals, Inc. Business Overview Table 90. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 92. INVENT Pharmaceuticals, Inc. Recent Development Table 93. Ipsen S.A. Company Information Table 94. Ipsen S.A. Business Overview Table 95. Ipsen S.A. Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Ipsen S.A. Neuroendocrine Tumor Drug Product Portfolio Table 97. Ipsen S.A. Recent Development Table 98. Karyopharm Therapeutics, Inc. Company Information Table 99. Karyopharm Therapeutics, Inc. Business Overview Table 100. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 102. Karyopharm Therapeutics, Inc. Recent Development Table 103. Lexicon Pharmaceuticals, Inc. Company Information Table 104. Lexicon Pharmaceuticals, Inc. Business Overview Table 105. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 107. Lexicon Pharmaceuticals, Inc. Recent Development Table 108. Midatech Pharma Plc . Company Information Table 109. Midatech Pharma Plc . Business Overview Table 110. Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Portfolio Table 112. Midatech Pharma Plc . Recent Development Table 113. Millennium Pharmaceuticals, Inc. Company Information Table 114. Millennium Pharmaceuticals, Inc. Business Overview Table 115. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 117. Millennium Pharmaceuticals, Inc. Recent Development Table 118. MolMed S.p.A. Company Information Table 119. MolMed S.p.A. Business Overview Table 120. MolMed S.p.A. Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. MolMed S.p.A. Neuroendocrine Tumor Drug Product Portfolio Table 122. MolMed S.p.A. Recent Development Table 123. Northwest Biotherapeutics, Inc. Company Information Table 124. Northwest Biotherapeutics, Inc. Business Overview Table 125. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 127. Northwest Biotherapeutics, Inc. Recent Development Table 128. OctreoPharm Sciences GmbH Company Information Table 129. OctreoPharm Sciences GmbH Business Overview Table 130. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Portfolio Table 132. OctreoPharm Sciences GmbH Recent Development Table 133. OXiGENE, Inc. Company Information Table 134. OXiGENE, Inc. Business Overview Table 135. OXiGENE, Inc. Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. OXiGENE, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 137. OXiGENE, Inc. Recent Development Table 138. Jiangsu Hengrui Medicine Co., Ltd. Company Information Table 139. Jiangsu Hengrui Medicine Co., Ltd. Business Overview Table 140. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Portfolio Table 142. Jiangsu Hengrui Medicine Co., Ltd. Recent Development Table 143. Novartis AG Company Information Table 144. Novartis AG Business Overview Table 145. Novartis AG Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Novartis AG Neuroendocrine Tumor Drug Product Portfolio Table 147. Novartis AG Recent Development Table 148. Eisai Company Information Table 149. Eisai Business Overview Table 150. Eisai Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Eisai Neuroendocrine Tumor Drug Product Portfolio Table 152. Eisai Recent Development Table 153. Key Raw Materials Table 154. Raw Materials Key Suppliers Table 155. Neuroendocrine Tumor Drug Distributors List Table 156. Neuroendocrine Tumor Drug Customers List Table 157. Research Programs/Design for This Report Table 158. Authors List of This Report Table 159. Secondary Sources Table 160. Primary Sources List of Figures Figure 1. Neuroendocrine Tumor Drug Product Image Figure 2. Global Neuroendocrine Tumor Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroendocrine Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neuroendocrine Tumor Drug Sales (2021-2032) & (W Units) Figure 5. Global Neuroendocrine Tumor Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Neuroendocrine Tumor Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. mTOR Protein Inhibitors Image Figure 10. Tyrosine Kinase 3 Inhibitors Image Figure 11. Growth Hormone Releasing Factor Antagonists Image Figure 12. Somatostatin Receptor Agonists Image Figure 13. Somatostatin Receptor Antagonists Image Figure 14. Others Image Figure 15. Global Neuroendocrine Tumor Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 16. Global Neuroendocrine Tumor Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Neuroendocrine Tumor Drug Sales Volume Share by Type (2021-2032) Figure 18. Global Neuroendocrine Tumor Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Neuroendocrine Tumor Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Neuroendocrine Tumor Drug Sales Value Share by Type (2021-2032) Figure 21. Hospital Image Figure 22. Clinic Image Figure 23. Others Image Figure 24. Global Neuroendocrine Tumor Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 25. Global Neuroendocrine Tumor Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Neuroendocrine Tumor Drug Sales Volume Share by Application (2021-2032) Figure 27. Global Neuroendocrine Tumor Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Neuroendocrine Tumor Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Neuroendocrine Tumor Drug Sales Value Share by Application (2021-2032) Figure 30. Global Neuroendocrine Tumor Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 31. Global Neuroendocrine Tumor Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Neuroendocrine Tumor Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Neuroendocrine Tumor Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Neuroendocrine Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 35. North America Neuroendocrine Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Neuroendocrine Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Neuroendocrine Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Neuroendocrine Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Neuroendocrine Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Neuroendocrine Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 41. South America Neuroendocrine Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Neuroendocrine Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Neuroendocrine Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Neuroendocrine Tumor Drug Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Neuroendocrine Tumor Drug Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • mTOR Protein Inhibitors
  • Tyrosine Kinase 3 Inhibitors
  • Growth Hormone Releasing Factor Antagonists
  • Somatostatin Receptor Agonists
  • Somatostatin Receptor Antagonists
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Exelixis, Inc.
  • Foresee Pharmaceuticals, LLC
  • Hutchison MediPharma Limited
  • Intezyne, Inc
  • INVENT Pharmaceuticals, Inc.
  • Ipsen S.A.
  • Karyopharm Therapeutics, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Midatech Pharma Plc .
  • Millennium Pharmaceuticals, Inc.
  • MolMed S.p.A.
  • Northwest Biotherapeutics, Inc.
  • OctreoPharm Sciences GmbH
  • OXiGENE, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Novartis AG
  • Eisai

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neuroendocrine Tumor Drug Sales Value (2021-2032)
  4. 1.2.2 Global Neuroendocrine Tumor Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Neuroendocrine Tumor Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neuroendocrine Tumor Drug Market Dynamics
  1. 2.1 Neuroendocrine Tumor Drug Industry Trends
  2. 2.2 Neuroendocrine Tumor Drug Industry Drivers
  3. 2.3 Neuroendocrine Tumor Drug Industry Opportunities and Challenges
  4. 2.4 Neuroendocrine Tumor Drug Industry Restraints
3 Neuroendocrine Tumor Drug Market by Company
  1. 3.1 Global Neuroendocrine Tumor Drug Company Revenue Ranking in 2025
  2. 3.2 Global Neuroendocrine Tumor Drug Revenue by Company (2021-2026)
  3. 3.3 Global Neuroendocrine Tumor Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Neuroendocrine Tumor Drug Average Price by Company (2021-2026)
  5. 3.5 Global Neuroendocrine Tumor Drug Company Ranking (2024-2026)
  6. 3.6 Global Neuroendocrine Tumor Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Neuroendocrine Tumor Drug Company Product Type and Application
  8. 3.8 Global Neuroendocrine Tumor Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neuroendocrine Tumor Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neuroendocrine Tumor Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neuroendocrine Tumor Drug Market by Type
  1. 4.1 Neuroendocrine Tumor Drug Type Introduction
  2. 4.1.1 mTOR Protein Inhibitors
  3. 4.1.2 Tyrosine Kinase 3 Inhibitors
  4. 4.1.3 Growth Hormone Releasing Factor Antagonists
  5. 4.1.4 Somatostatin Receptor Agonists
  6. 4.1.5 Somatostatin Receptor Antagonists
  7. 4.1.6 Others
  8. 4.2 Global Neuroendocrine Tumor Drug Sales Volume by Type
  9. 4.2.1 Global Neuroendocrine Tumor Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Neuroendocrine Tumor Drug Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Neuroendocrine Tumor Drug Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Neuroendocrine Tumor Drug Sales Value by Type
  13. 4.3.1 Global Neuroendocrine Tumor Drug Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Neuroendocrine Tumor Drug Sales Value by Type (2021-2032)
  15. 4.3.3 Global Neuroendocrine Tumor Drug Sales Value Share by Type (2021-2032)
5 Neuroendocrine Tumor Drug Market by Application
  1. 5.1 Neuroendocrine Tumor Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Neuroendocrine Tumor Drug Sales Volume by Application
  6. 5.2.1 Global Neuroendocrine Tumor Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neuroendocrine Tumor Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Neuroendocrine Tumor Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Neuroendocrine Tumor Drug Sales Value by Application
  10. 5.3.1 Global Neuroendocrine Tumor Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Neuroendocrine Tumor Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Neuroendocrine Tumor Drug Sales Value Share by Application (2021-2032)
6 Neuroendocrine Tumor Drug Regional Sales and Value Analysis
  1. 6.1 Global Neuroendocrine Tumor Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuroendocrine Tumor Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Neuroendocrine Tumor Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Neuroendocrine Tumor Drug Sales by Region (2027-2032)
  5. 6.3 Global Neuroendocrine Tumor Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neuroendocrine Tumor Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neuroendocrine Tumor Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neuroendocrine Tumor Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Neuroendocrine Tumor Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neuroendocrine Tumor Drug Sales Value (2021-2032)
  12. 6.6.2 North America Neuroendocrine Tumor Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neuroendocrine Tumor Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Neuroendocrine Tumor Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neuroendocrine Tumor Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neuroendocrine Tumor Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neuroendocrine Tumor Drug Sales Value (2021-2032)
  21. 6.9.2 South America Neuroendocrine Tumor Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neuroendocrine Tumor Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neuroendocrine Tumor Drug Sales Value Share by Country, 2025 VS 2032
7 Neuroendocrine Tumor Drug Country-level Sales and Value Analysis
  1. 7.1 Global Neuroendocrine Tumor Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neuroendocrine Tumor Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neuroendocrine Tumor Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Neuroendocrine Tumor Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Neuroendocrine Tumor Drug Sales by Country (2027-2032)
  6. 7.4 Global Neuroendocrine Tumor Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neuroendocrine Tumor Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neuroendocrine Tumor Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neuroendocrine Tumor Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neuroendocrine Tumor Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neuroendocrine Tumor Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Exelixis, Inc.
  2. 8.1.1 Exelixis, Inc. Company Information
  3. 8.1.2 Exelixis, Inc. Business Overview
  4. 8.1.3 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Exelixis, Inc. Neuroendocrine Tumor Drug Product Portfolio
  6. 8.1.5 Exelixis, Inc. Recent Developments
  7. 8.2 Foresee Pharmaceuticals, LLC
  8. 8.2.1 Foresee Pharmaceuticals, LLC Company Information
  9. 8.2.2 Foresee Pharmaceuticals, LLC Business Overview
  10. 8.2.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Portfolio
  12. 8.2.5 Foresee Pharmaceuticals, LLC Recent Developments
  13. 8.3 Hutchison MediPharma Limited
  14. 8.3.1 Hutchison MediPharma Limited Company Information
  15. 8.3.2 Hutchison MediPharma Limited Business Overview
  16. 8.3.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Portfolio
  18. 8.3.5 Hutchison MediPharma Limited Recent Developments
  19. 8.4 Intezyne, Inc
  20. 8.4.1 Intezyne, Inc Company Information
  21. 8.4.2 Intezyne, Inc Business Overview
  22. 8.4.3 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Intezyne, Inc Neuroendocrine Tumor Drug Product Portfolio
  24. 8.4.5 Intezyne, Inc Recent Developments
  25. 8.5 INVENT Pharmaceuticals, Inc.
  26. 8.5.1 INVENT Pharmaceuticals, Inc. Company Information
  27. 8.5.2 INVENT Pharmaceuticals, Inc. Business Overview
  28. 8.5.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
  30. 8.5.5 INVENT Pharmaceuticals, Inc. Recent Developments
  31. 8.6 Ipsen S.A.
  32. 8.6.1 Ipsen S.A. Company Information
  33. 8.6.2 Ipsen S.A. Business Overview
  34. 8.6.3 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Ipsen S.A. Neuroendocrine Tumor Drug Product Portfolio
  36. 8.6.5 Ipsen S.A. Recent Developments
  37. 8.7 Karyopharm Therapeutics, Inc.
  38. 8.7.1 Karyopharm Therapeutics, Inc. Company Information
  39. 8.7.2 Karyopharm Therapeutics, Inc. Business Overview
  40. 8.7.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
  42. 8.7.5 Karyopharm Therapeutics, Inc. Recent Developments
  43. 8.8 Lexicon Pharmaceuticals, Inc.
  44. 8.8.1 Lexicon Pharmaceuticals, Inc. Company Information
  45. 8.8.2 Lexicon Pharmaceuticals, Inc. Business Overview
  46. 8.8.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
  48. 8.8.5 Lexicon Pharmaceuticals, Inc. Recent Developments
  49. 8.9 Midatech Pharma Plc .
  50. 8.9.1 Midatech Pharma Plc . Company Information
  51. 8.9.2 Midatech Pharma Plc . Business Overview
  52. 8.9.3 Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Portfolio
  54. 8.9.5 Midatech Pharma Plc . Recent Developments
  55. 8.10 Millennium Pharmaceuticals, Inc.
  56. 8.10.1 Millennium Pharmaceuticals, Inc. Company Information
  57. 8.10.2 Millennium Pharmaceuticals, Inc. Business Overview
  58. 8.10.3 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
  60. 8.10.5 Millennium Pharmaceuticals, Inc. Recent Developments
  61. 8.11 MolMed S.p.A.
  62. 8.11.1 MolMed S.p.A. Company Information
  63. 8.11.2 MolMed S.p.A. Business Overview
  64. 8.11.3 MolMed S.p.A. Neuroendocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 MolMed S.p.A. Neuroendocrine Tumor Drug Product Portfolio
  66. 8.11.5 MolMed S.p.A. Recent Developments
  67. 8.12 Northwest Biotherapeutics, Inc.
  68. 8.12.1 Northwest Biotherapeutics, Inc. Company Information
  69. 8.12.2 Northwest Biotherapeutics, Inc. Business Overview
  70. 8.12.3 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
  72. 8.12.5 Northwest Biotherapeutics, Inc. Recent Developments
  73. 8.13 OctreoPharm Sciences GmbH
  74. 8.13.1 OctreoPharm Sciences GmbH Company Information
  75. 8.13.2 OctreoPharm Sciences GmbH Business Overview
  76. 8.13.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Portfolio
  78. 8.13.5 OctreoPharm Sciences GmbH Recent Developments
  79. 8.14 OXiGENE, Inc.
  80. 8.14.1 OXiGENE, Inc. Company Information
  81. 8.14.2 OXiGENE, Inc. Business Overview
  82. 8.14.3 OXiGENE, Inc. Neuroendocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 OXiGENE, Inc. Neuroendocrine Tumor Drug Product Portfolio
  84. 8.14.5 OXiGENE, Inc. Recent Developments
  85. 8.15 Jiangsu Hengrui Medicine Co., Ltd.
  86. 8.15.1 Jiangsu Hengrui Medicine Co., Ltd. Company Information
  87. 8.15.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview
  88. 8.15.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Portfolio
  90. 8.15.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
  91. 8.16 Novartis AG
  92. 8.16.1 Novartis AG Company Information
  93. 8.16.2 Novartis AG Business Overview
  94. 8.16.3 Novartis AG Neuroendocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Novartis AG Neuroendocrine Tumor Drug Product Portfolio
  96. 8.16.5 Novartis AG Recent Developments
  97. 8.17 Eisai
  98. 8.17.1 Eisai Company Information
  99. 8.17.2 Eisai Business Overview
  100. 8.17.3 Eisai Neuroendocrine Tumor Drug Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Eisai Neuroendocrine Tumor Drug Product Portfolio
  102. 8.17.5 Eisai Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neuroendocrine Tumor Drug Value Chain Analysis
  2. 9.1.1 Neuroendocrine Tumor Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neuroendocrine Tumor Drug Sales Mode & Process
  6. 9.2 Neuroendocrine Tumor Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neuroendocrine Tumor Drug Distributors
  9. 9.2.3 Neuroendocrine Tumor Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst